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Abstract
Background:Cyclophosphamide (CP) is a well-known alkylating anticancer agent used
in the treatment of various malignant and non-malignant tumors. CP may also cause
a variety of adverse effects, including reproductive toxicity. Amifostine is known as a
cytoprotective drug having antioxidant properties.
Objective: To evaluate the possible beneficial effects of amifostine on testicular toxicity
induced by CP in rats.
Materials and Methods: A total of 35 Sprague-Dawley rats were used in this
experimental study. The CP group animals received a single dose of 200 mg/kg
CP on Day 8 by intraperitoneal injection and were left untreated for the following
seven days. The two remaining groups of animals were treated with 200 mg/kg/day
amifostine (AMF 200) and 400 mg/kg/day amifostine (AMF 400) for seven days prior
to and following a single intraperitoneal injection of CP. Morphometrical analysis
and histological examination of testicular tissue were performed. Serum testosterone,
luteinizing hormone, and follicle-stimulating hormone levels were measured in serum
using commercial ELISA kits. The epidydimal sperm count was determined.
Results: The tubular epithelial height in the testis was significantly higher in the
AMF400 group compared to other groups (p < 0.001). Animals in the AMF400 group
showed minimal debris in the tubules, no Sertoli cell damage, and the Johnsen
scores were slightly higher in the AMF400 group. The epididymal sperm count was
significantly lower in the CP-administered animals compared to the control animals and
was significantly higher in the AMF200 and AMF400 groups compared to the CP group
(p = 0.006, and p = 0.019 respectively).
Conclusion: Amifostine, at a dose of 400 mg/kg, may have a protective effect on
testicular damage induced by CP in rats.
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1. Introduction
Cyclophosphamide (CP) is a well-known alky-
lating anticancer agent used in the treatment of
various malignant and non-malignant tumors (1).
It is also used as an immunosuppressive agent
to prevent organ transplant rejection and to treat
several autoimmune diseases. Although it is widely
used in clinical practice, CP may also cause a
variety of adverse effects, including reproductive
toxicity, which is particularly significant in younger
patients (2, 3). Although the exact mechanism of
testicular toxicity induced by CP is unclear, there is
clear evidence that CP disrupts the redox balance
of tissues and induces oxidative stress (3–5).
The balance between oxidation and the antiox-
idative defense system is known to play a role
in spermatogenesis and fertility (3, 6–8). Other
pathogenetic mechanisms thought to play a role
in CP-induced testicular toxicity include decreased
DNA synthesis in spermatogonia, decreased pro-
tein synthesis in spermatid, apoptosis and sperm
dysfunction (5, 9). Many antioxidants and nutri-
tional supplements have been used in experimen-
tal models to overcome CP-induced reproductive
toxicity (3–5, 9), with most of these reporting
encouraging results.
Amifostine was initially developed in order to
protect people from the effects of nuclear weapons
and was later developed as a cytoprotection for
radiation therapy and chemotherapy (10). Ami-
fostine (AMF; S-2-(3-aminopropylamino) ethylphos-
phothiotic acid) is known as a cytoprotective
drug having antioxidant properties. It is a prodrug
metabolized to an active form known as WR-
1065 by interaction with membrane-bound alkaline
phosphatase (ALP) (10, 11). WR-1065 is the metabo-
lite responsible for the radical scavenging and
antioxidant properties of amifostine (11).
Although amifostine has been shown to have no
detrimental effects of doxorubicin on testis tissue
(12, 13), a number of previous studies suggest that
amifostine reduces seminiferous epithelium dam-
age, with no improvement in fertility, in doxorubicin-
treated rats (14), protects rats from cisplatin-induced
testicular toxicity (15) and has a radioprotective
effect on spermiogenetic cells when used prior to
radiation (16).
The aim of the present study is to evaluate
the possible beneficial effects of a cytoprotectant
agent amifostine on testicular toxicity induced
by CP, focusing on the cytoprotective effects of
amifostine.
2. Materials and Methods
2.1. Study animals and treatments
A total of 35 Sprague-Dawley rats weighing
200–250 gr were used in the study. They were
housed in ventilated rooms at a temperature of 24
+ 2°C with a 12 hr light/dark cycle, and a humidity
of 60 + 5% and were fed with a standard pelleted
diet with free access to water.
The rats were divided into four groups, each
containing seven animals. The control group ani-
mals (C) received no intervention. The CP group
animals received a single dose of 200 mg/kg CP
on day 8 by intraperitoneal (IP) injection and were
left untreated for the following seven days. The two
remaining groups of animals (AMF 200 and AMF
400) were treated with 200 mg/kg/day amifostine
and 400 mg/kg/day amifostine for seven days prior
to and following a single IP injection of 200 mg/kg
CP.
At the end of the treatment protocol, the rats
were sacrificed by decapitation. The animals were
then weighed with intracardiac blood samples
obtained under ether anesthesia. After killing the
animals with a high-dose ether, both testes were
removed from each and weighed. Blood samples
were centrifuged to obtain serum samples which
were stored at 70°C until analysis. One of the
testes was used for histological analysis and the
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other was weighed and stored at 70°C until the dry
weight could be determined.
2.2. Morphometrical evaluations
The body weights (BWs) of the animals were
determined at the start of the study protocol. For
a determination of the dry weight of testis, the
samples stored at 70°C were dried in an oven at
60°C. The ratio of dry weight of testis (TW𝑑 ) to its
wet weight (TW𝑤) was calculated as follows:
TW𝑑/𝑤= TW𝑑/TW𝑤.
Additionally, the ratio of TW𝑤 to body weight
(TW/BW) was also calculated to determine the
relative testicular weight.
2.3. Testis histology
Epididymis was removedwith the testes andwas
used to evaluate sperm count and morphology.
The epididymis was immediately put into 1 mL
of Phosphate-buffered saline (PBS) and cut into
small pieces. After vortexing for 2–3 min, 50 µL of
supernatant was put on aMakler counting chamber
(Sefi Medical Instruments, Haifa, Israel) to assess
sperm count and morphology. Morphometric anal-
ysis was performed on all of the animals using
image-analyzing software. Epithelial height was
measured in seminiferous tubules at six areas for
six experimental subjects per group.
Testicular tissue used for histological analy-
sis was fixed in 4% paraformaldehyde and then
embedded in paraffin blocks. Tissue sections
cut at a thickness of 5 µm were stained with
hematoxylin and eosin (H&E). The stained sections
were evaluated under a light microscope. Tubu-
loseminiferous epithelial height was measured
in order to determine the histological changes
in H & E-stained preparations. A Johnsen scor-
ing system was used to evaluate the germ
cells in testicular tubules (17). Germ cells were
scored from 1 to 10 according to their num-
ber and cell type of highest maturation in each
tubule.
2.4. Serum testosterone, LH, and FSH
analyses
Serum testosterone, LH, and FSH levels were
determined using commercially available kits for
rats (USCN Life Science Inc., Wuhan, China).
2.5. Ethical consideration
All animal experiments were conducted accord-
ing to the guidelines for the care and use of
laboratory animals with consent obtained from the
local ethics committee (26/04/2011-205).
2.6. Statistical analysis
The results are expressed as Mean ± SEM. A
statistical analysis was performed using an SPSS
21.0 (Predictive Analytics, Chicago, IL) package pro-
gram. The difference between groups was deter-
mined using a one-way ANOVA and a Kruskal-




The BW of the animals did not differ among the
study groups (p > 0.05). Accordingly, there was no
significant difference in TW𝑑/𝑤 and TW/BW among
the groups (p > 0.05) (Table I).
3.2. Testis histology
The epididymal sperm count was significantly
lower in the CP-administered animals compared
to the healthy control animals (p < 0.01). On the
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other hand, 200 mg/kg and 400 mg/kg amifostine
resulted in a significantly higher sperm count
compared to the CP group of animals (p < 0.01 and
p < 0.05, respectively) (Figure 1).
The tubular epithelial height in the testis was
significantly lower in the CP, AMF200, and AMF400
groups compared to the control animals (p < 0.001
for each). On the other hand, it was significantly
higher in the AMF400 group compared to the CP
and AMF200 groups (p < 0.001 for both) (Figure 2).
The histological appearance of the testis is
shown in Figure 3. H&E staining showed increased
debris at the center of the tubules and damage in
Sertoli cells in the CP and AMF200 groups. On the
other hand, animals in the AMF400 group showed
minimal debris in the tubules and no Sertoli cell
damage (Figure 3).
Johnsen scores were found to be significantly
decreased in the CP and AMF200 groups com-
pared to the control animals (p > 0.01) (Figure 4). It
should be noted that despite not being statistically
significant, the scores were slightly higher in the
AMF400 group.
3.3. Serum testosterone, LH, and FSH
analyses
The serum testosterone, LH and FSH levels
measured by ELISA kits showed no difference
among the groups (p > 0.05) (Figure 5).
Table I. Body and organ weights in animals
Body weight (g) TW𝑑/𝑤(mg/mg) TW/BW (mg/g)
CONTROL 202.9 ± 12.2 0.149 ± 0.40 0.0071 ± 0.003
CP 201.4 ± 13.5 0.165 ± 0.013 0.0063 ± 0.0005
AMF200 225.0 ± 26.9 0.171 ± 0.017 0.0055 ± 0.0004
AMF400 212.9 ± 29.8 0.175 ± 0.022 0.0057 ± 0.0003
Note: CP: Cyclophosphamide group; AMF200 and AMF400: animal groups treated with 200 mg/kg/day and 400 mg/kg/day
amifostine; TW𝑑/𝑤: ratio of dry to wet weight of testis; TW/BW: ratio of testicular weight to body weight
Figure 1. Epididymal sperm count. Differences are given compared to the control group (*) or CP group ( ). CP: Cyclophosphamide
group; AMF200 and AMF400: animal groups treated with 200 mg/kg/day and 400 mg/kg/day amifostine.
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Figure 2. Testicular tubule epithelial height. Differences are given compared to the control group (*) or CP group ( ). CP:
cyclophosphamide group and AMF200 group(¥); AMF200 and AMF400: animal groups treated with 200 mg/kg/day and 400
mg/kg/day amifostine, p < 0.001.
Figure 3. Histological analysis in the HE-stained testis preparations: (a) Control; (b) CP group; (c) AMF200 group; (d) AMF400
group.
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Figure 4. Johnsen scores. Differences are given compared to the control group (*); AMF200 and AMF400: animal groups treated
with 200 mg/kg/day and 400 mg/kg/day amifostine p < 0.002.
Figure 5. Serum testosterone, LH and FSH levels. CP: cyclophosphamide group; AMF200 and AMF400: animal groups treated
with 200 mg/kg/day and 400 mg/kg/day amifostine.
4. Discussion
Amifostine is a chemoprotective pro-drug trans-
formed into its active form by ALP (18). Many pre-
vious studies have shown that amifostine may pro-
tect several tissues including bone marrow, periph-
eral nerves, heart, kidney, and salivary glands from
the cytotoxic effects of an alkylating agent without
compromising their antitumor activities (18).
The current study evaluates the protective effect
of amifostine on testicular dysfunction induced by
CP in male rats.
One remarkable finding in the present study is
an increased sperm count in the amifostine-treated
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animals. The epididymal sperm count decreased
significantly in animals treated only with CP, sug-
gesting testicular dysfunction induced by CP (p
< 0.01). However, amifostine, both in doses of
200 mg/kg/day and 400 mg/kg/day, significantly
reversed this decrease in sperm count induced by
CP (p < 0.01 and p < 0.05, respectively) (Figure
1). Nalca et al previously investigated the possible
protective effect of amifostine on radiation-induced
testicular damage. Similar to our findings, the
authors reported an increased primary spermato-
cyte count with the amifostine treatment compared
to radiation-treated animals (19), suggesting that
amifostine may have the potential to protect the
testis from damage.
Testicular epithelial height was significantly
lower in the CP, AMF200, and AMF400 groups
compared to the control group animals (p <
0.01) (Figure 2). It is not unexpected to have
decreased epithelial height in animals treated
with CP. The most remarkable finding was a
significantly increased epithelial height in the
AMF400 group compared to the CP group and
even the AMF200 group. Epithelial height was
also higher in the AMF200 group compared to
the CP group with no statistical difference, sug-
gesting that amifostine may protect the testic-
ular structure against CP-induced damage in a
dose-dependent manner. In a similarly designed
study, Lirdi et al studied the effect of amifos-
tine on testicular damage induced by cisplatin,
a cytotoxic agent (15). The authors found similar
results to those of our study and concluded that
amifostine may protect testicular tissue from the
adverse effects of cisplatin. On the other hand,
Vendramini et al found that doxorubicin treat-
ment decreases seminipherous epithelial height
in prepubertal male rats which was prevented
with the administration of a 400 mg/kg ami-
fostine treatment (14). As can be seen in the
aforementioned two studies, a 400 mg/kg ami-
fostine treatment seems to have a protective
effect on testicular tissue against chemotherapy-
induced damage. Accordingly, amifostine was
also effective at a dose of 400 mg/kg com-
pared to a dose of 200 mg/kg. All of these
results indicating that amifostine may protect tes-
ticular tissue from damage suggest that ami-
fostine could be further studied for use as
a chemoprotective agent, particularly in young
males.
All histological findings also support the
abovementioned findings (Figure 3). Decreased
debris in the center of tubules suggests that
400 mg/kg amifostine might protect the CP-
induced testicular damage. Johnsen scores
were found to be significantly lower in the
CP and AMF200 groups (Figure 4). Although
not statistically significant, the scores were
higher in the AMF400 group, suggesting a dose-
dependent increase for amifostine in the Johnsen
scores.
There were no significant differences in the
testosterone, LH and FSH levels among the groups
(Figure 5). Jahnukainen et al studied the protective
effect of amifostine on the testicular tissue of
immature rats and also found no significant differ-
ence between the groups in serum testosterone
levels (12). Therefore, the authors concluded that
amifostine may not have a protective effect on
testis. Although our serum hormone levels are
similar to those observed by Jahnukainen et al, our
histological findings suggest a marked improve-
ment in testicular tissue (12). Accordingly, Lirdi et al
found that amifostine preserved the seminipherous
epithelium of male rats from the deleterious effects
of cisplatin and conclude that amifostin may be
a beneficial option for infant and young male
patients treated with chemotherapeutic agents
(15).
Although there have been many studies on
the potential protective effects of amifostine from
chemotherapy-induced adverse effects on several
tissues, to our knowledge, there has been no in
vivo study investigating the effect of amifostine on
CP-induced testicular toxicity. In a germ cell study,
BirGolkar-Narenji et al investigated the protective
effect of amifostine on damage induced by CP
in mice oocytes (20). The authors suggest that
amifostine may protect the mice oocytes from
apoptosis induced by CP, supporting our in vivo
results.
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5. Conclusion
Cyclophosphamide has been suggested that CP
results in germ cell damage in both males and
females (21). Amifostine, approved as a chemo-
protective agent by the FDA, is known to have
cytoprotective effects. It acts as a free radical
scavenger and ameliorates the effects of ionizing
radiation and DNA damage (22). The current study
on the possible protective effects of amifostine on
testicular toxicity induced by CP in rats suggests
that amifostine, at a dose of 400 mg/kg, may have
a protective effect on testicular damage. This is of
importance for male patients undergoing cancer
treatment wishing to maintain reproductive ability.
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